N@N

AMRI Appoints New Director of DMPK,;; Further Strengthening its Integrated Discovery Biology and Chemistry Platform

^{Published on 2011-09-12 05:11:50 - Market Wire}
 

ALBANY, N.Y.--([ BUSINESS WIRE ])--AMRI (NASDAQ: AMRI) announced today that Charles Jensen, Ph.D., has joined AMRI as director of Drug Metabolism and Pharmacokinetics (DMPK), reporting to Bruce J. Sargent, Ph.D., Senior Vice President of Drug Discovery.

Dr. Jensen brings more than 20 years of relevant experience, working in the fields of drug metabolism and toxicology in the pharmaceutical industry. His strong technical background and project management experience will strengthen AMRIa™s capabilities in the DMPK arena and further enhance AMRIa™s global platform of integrated discovery biology and chemistry services.

Drug discovery capabilities at AMRI support the entire drug-discovery platform including DMPK, in vitro biology, CADD, synthetic chemistry and medicinal chemistry. DMPK science is an important component of drug discovery programs and utilizes in vitro and in vivo experiments to evaluate how candidate drugs may be absorbed, distributed in various tissues or organs, metabolized and otherwise interact with various organs and systems beyond the intended drug target. Combining these broad capabilities has contributed to the companya™s success in helping its customers discover more than 70 preclinical nominations and clinical candidates during the past 20 years.

Dr. Jensen has gained experience with both discovery and development phase DMPK and toxicology through his career, which has included 15 years at Eli Lilly and Co., where he ultimately became Senior Study Director for Drug Development Services for In Vitro Technologies. Prior to Lilly, Dr. Jensen worked for RTI Health Solutions, where he established a full-service in vitro DMPK-toxicology laboratory and developed a robust intestinal permeability/Pgp transport model.

He received a Ph.D. in Pharmacology from The University of Virginia in 1984 and has served as author or Principal Investigator on more than 200 submitted reports and 30 peer-reviewed publications.

aAt AMRI, we consider early ADMET profiling and pharmacokinetic analysis to be crucial components of the drug discovery process, and we are excited to have Dr. Jensen join us with his substantial experience in these fields. His DMPK expertise adds additional depth to AMRIa™s leading drug discovery team and will help position the company as it expands its involvement with fully integrated discovery biology and chemistry programs,a said Dr. Sargent.

About AMRI:

Founded in 1991, Albany Molecular Research, Inc. provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies, and cost models.